若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

EasySep™人Gamma/Delta T细胞分选试剂盒

免疫磁珠负选分选不带标记的人γ/δ T细胞

产品号 #(选择产品)

产品号 #19255_C

免疫磁珠负选分选不带标记的人γ/δ T细胞

产品优势

  • 操作简单、快捷,且无需分离柱
  • 纯度高达97%
  • 分选得到的细胞不带标记

产品组分包括

  • EasySep™人Gamma/Delta T细胞分选试剂盒(产品号 #19255)
    • EasySep™人Gamma/Delta T细胞分选抗体混合物,1 mL
    • EasySep™ D2 Magnetic Particles磁珠,3 x 1 mL
  • RoboSep™人Gamma/Delta T细胞分选试剂盒(产品号 #19255RF)
    • EasySep™人Gamma/Delta T细胞分选抗体混合物,1 mL
    • EasySep™ D2 Magnetic Particles磁珠,3 x 1 mL
    • RoboSep™ 缓冲液(产品号 #20104)
    • RoboSep™过滤吸头(产品号 #20125)
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品

总览

使用EasySep™人γ/δ T细胞分选试剂盒,可轻松高效地从新鲜或冻存的人外周血单个核细胞(PBMCs)或裂解的白细胞单采术样本中,通过免疫磁珠负选获得高纯度的人γ/δ T细胞。EasySep™技术结合单克隆抗体的特异性和无柱磁分选系统的简便性,已在发表的研究中广泛应用超过20年。

在该EasySep™负选流程中,非目的细胞(包括CD16和CD25细胞)会被抗体复合物与磁珠标记。使用EasySep™磁极吸附后,通过简单地将目的细胞倾倒或吸取至一个新的试管中,即可将被磁珠标记的细胞与不带标记的目的细胞分离开来。经磁珠分选后,目的γ/δ T细胞可立即用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

了解更多EasySep™免疫磁珠技术的工作原理,或者如何通过RoboSep™实现全自动化免疫磁珠细胞分选。或者选择用EasySep™人Gamma/Delta T细胞分选试剂盒分离的即用型、符合伦理来源的原代人γ/δ T细胞。探索更多为您的实验流程优化的产品,包括培养基、补充剂、抗体等。

在该EasySep™负选流程中,非目的细胞(包括CD16和CD25细胞)会被抗体复合物与磁珠标记。使用EasySep™磁极吸附后,通过简单地将目的细胞倾倒或吸取至一个新的试管中,即可将被磁珠标记的细胞与不带标记的目的细胞分离开来。经磁珠分选后,目的γ/δ T细胞可立即用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

了解更多EasySep™免疫磁珠技术的工作原理,或者如何通过RoboSep™实现全自动化免疫磁珠细胞分选。或者选择用EasySep™人Gamma/Delta T细胞分选试剂盒分离的即用型、符合伦理来源的原代人γ/δ T细胞。探索更多为您的实验流程优化的产品,包括培养基、补充剂、抗体等。

在该EasySep™负选流程中,非目的细胞(包括CD16和CD25细胞)会被抗体复合物与磁珠标记。使用EasySep™磁极吸附后,通过简单地将目的细胞倾倒或吸取至一个新的试管中,即可将被磁珠标记的细胞与不带标记的目的细胞分离开来。经磁珠分选后,目的γ/δ T细胞可立即用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

了解更多EasySep™免疫磁珠技术的工作原理,或者如何通过RoboSep™实现全自动化免疫磁珠细胞分选。或者选择用EasySep™人Gamma/Delta T细胞分选试剂盒分离的即用型、符合伦理来源的原代人γ/δ T细胞。探索更多为您的实验流程优化的产品,包括培养基、补充剂、抗体等。

在该EasySep™负选流程中,非目的细胞(包括CD16和CD25细胞)会被抗体复合物与磁珠标记。使用EasySep™磁极吸附后,通过简单地将目的细胞倾倒或吸取至一个新的试管中,即可将被磁珠标记的细胞与不带标记的目的细胞分离开来。经磁珠分选后,目的γ/δ T细胞可立即用于流式细胞术、细胞培养或DNA/RNA提取等下游应用。

了解更多EasySep™免疫磁珠技术的工作原理,或者如何通过RoboSep™实现全自动化免疫磁珠细胞分选。或者选择用EasySep™人Gamma/Delta T细胞分选试剂盒分离的即用型、符合伦理来源的原代人γ/δ T细胞。探索更多为您的实验流程优化的产品,包括培养基、补充剂、抗体等。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
T 细胞,T 细胞,其他亚群
 
种属

 
样本来源
Leukapheresis,PBMC
 
筛选方法
Negative
 
应用
细胞分选
 
品牌
EasySep,RoboSep
 
研究领域
免疫
 

实验数据

Typical EasySep™ Human Gamma/Delta T Cell Isolation Profile

Figure 1. Typical EasySep™ Human Gamma/Delta T Cell Isolation Profile

Starting with fresh PBMCs, the gamma/delta TCR+CD3+ cell content of the isolated fraction typically ranges from 90 - 97%. In the above example, the purities of the start and final isolated fractions are 2.5% and 92.9%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
19255
Lot #
All
Language
English
Catalog #
19255RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
19255
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
19255
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
19255RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
19255RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
19255RF
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

相关材料与文献

技术资料 (8)

常见问题

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 µL. Samples containing 2x107 cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

文献 (3)

A genome-scale screen for synthetic drivers of T cell proliferation. M. Legut et al. Nature 2022 mar

Abstract

The engineering of autologous patient T cells for adoptive cell therapies has revolutionized the treatment of several types of cancer1. However, further improvements are needed to increase response and cure rates. CRISPR-based loss-of-function screens have been limited to negative regulators of T cell functions2-4 and raise safety concerns owing to the permanent modification of the genome. Here we identify positive regulators of T cell functions through overexpression of around 12,000 barcoded human open reading frames (ORFs). The top-ranked genes increased the proliferation and activation of primary human CD4+ and CD8+ T cells and their secretion of key cytokines such as interleukin-2 and interferon-$\gamma$. In addition, we developed the single-cell genomics method OverCITE-seq for high-throughput quantification of the transcriptome and surface antigens in ORF-engineered T cells. The top-ranked ORF-lymphotoxin-$\beta$ receptor (LTBR)-is typically expressed in myeloid cells but absent in lymphocytes. When overexpressed in T cells, LTBR induced profound transcriptional and epigenomic remodelling, leading to increased T cell effector functions and resistance to exhaustion in chronic stimulation settings through constitutive activation of the canonical NF-$\kappa$B pathway. LTBR and other highly ranked genes improved the antigen-specific responses of chimeric antigen receptor T cells and ?? T cells, highlighting their potential for future cancer-agnostic therapies5. Our results provide several strategies for improving next-generation T cell therapies by the induction of synthetic cell programmes.
1$\alpha$,25(OH)2D3 reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells. P. Li et al. Journal for immunotherapy of cancer 2022 mar

Abstract

BACKGROUND Epidemiological surveys have revealed that low serum vitamin D level was correlated with increased risk of tumors. Dysfunctional T cells in patients with tumor are characterized as exhausted with high levels of immune checkpoint receptors (ICRs). However, whether the reduced level of vitamin D in patients with cancer correlates with cytotoxic T-cell exhaustion is unknown. METHODS Periphery blood samples from 172 patients with non-small cell lung cancer (NSCLC) were prospectively collected. Patients with NSCLC received one course of intravenous docetaxel (75 mg/m2) followed by treatment with or without rocaltrol at a dose of 0.5-2.0 µg/day for total of 3 weeks. We performed phenotypical and functional analysis of T-cell through flow cytometry. Vitamin D receptor (VDR) knockout and overexpression CD8+ and V$\delta$2+ T cells were constructed using Cas9-gRNA targeted and overexpressing approaches to identify 1$\alpha$,25(OH)2D3/VDR-mediated transcription regulation for ICRs or antitumor activity in T cells. RESULTS We show that serum level of vitamin D is negatively correlated with expression of programmed cell death-1 (PD-1), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and T-cell immunoglobulin and mucin-domain containing-3 (Tim-3), but positively correlated with CD28 expression on CD8+ and V$\gamma$9V$\delta$2+ T cells in patients with NSCLC. 1$\alpha$,25(OH)2D3, the active form of vitamin D, promotes the nuclear translocation of VDR, which binds to the promoter region of Pdcd1, Tim3, and Tigit genes and inhibits their expression. Besides, 1$\alpha$,25(OH)2D3 pretreatment also promotes the methylation of CpG island in the promoter region of the Pdcd1 gene and increases H3K27 acetylation at the promoter region of the Cd28 gene, which leads to surface PD-1 downregulation and CD28 upregulation, respectively. We further reveal that VDR-mediated Ca2+ influx enhanced expression of Th1 cytokines via T-cell receptor activation. Functionally, 1$\alpha$,25(OH)2D3 pretreated CD8+ T cells or V$\gamma$9V$\delta$2+ T cells showed increased Th1 cytokine production and enhanced antitumor immunity. Finally, oral 1$\alpha$,25(OH)2D3 could also decrease expression of PD-1, Tim-3, TIGIT and increase expression of CD28, resulting in cytokine production (associated with antitumor immunity) by cytotoxic T cells of patients with NSCLC. CONCLUSIONS Our findings uncover the pleiotropic effects of 1$\alpha$,25(OH)2D3 in rescuing the exhausted phenotype of human cytotoxic T cells in patients with tumor and in promoting their antitumor immunity. TRIAL REGISTRATION NUMBER ChiCTR2100051135.
Targeted glycan degradation potentiates the anticancer immune response in vivo. M. A. Gray et al. Nature chemical biology 2020 dec

Abstract

Currently approved immune checkpoint inhibitor therapies targeting the PD-1 and CTLA-4 receptor pathways are powerful treatment options for certain cancers; however, most patients across cancer types still fail to respond. Consequently, there is interest in discovering and blocking alternative pathways that mediate immune suppression. One such mechanism is an upregulation of sialoglycans in malignancy, which has been recently shown to inhibit immune cell activation through multiple mechanisms and therefore represents a targetable glycoimmune checkpoint. Since these glycans are not canonically druggable, we designed an $\alpha$HER2 antibody-sialidase conjugate that potently and selectively strips diverse sialoglycans from breast cancer cells. In syngeneic breast cancer models, desialylation enhanced immune cell infiltration and activation and prolonged the survival of mice, an effect that was dependent on expression of the Siglec-E checkpoint receptor found on tumor-infiltrating myeloid cells. Thus, antibody-sialidase conjugates represent a promising modality for glycoimmune checkpoint therapy.

更多信息

更多信息
种属 Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • Easy 50 EasySep™ Magnet (Catalog #18002) • RoboSep™-S (Catalog #21000)
样本来源 Leukapheresis, PBMC
Selection Method Negative
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.